-Reuters
Akoya Biosciences And Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval For KR-HT5 In China To Support Next Generation Pathology Clinical Workflows
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya